Microbicides: latest news

Microbicides resources

  • Microbicides

    Microbicides are any substances which protect people against infection by microbes, such as viruses or bacteria, on contact with those microbes....

    From: Preventing HIV

    Information level Level 4
  • Microbicides

    A microbicide is a topical agent that, when applied to a mucosal surface, serves as a barrier to infection. Microbicides can come in the form of...

    From: HIV transmission & testing

    Information level Level 4

Microbicides features

Microbicides news from aidsmap

More news

Microbicides news selected from other sources

  • Will Nutland: The emergence of the end of HIV

    Will Nutland proposes that instead of the Hollywood style ‘end of AIDS moment’ fantasy, the end of AIDS will be a process with a number of emerging endpoints. In this eye-opening talk, Will introduces PrEP and rectal microbicides and discusses their efficacy and levels of acceptability. He surmises that the end might happen without us even noticing.

    10 November 2015 | TEDx Talks / You Tube
  • Why Microbicides for HIV Prevention Are Still Necessary in the Treatment-as-Prevention Era

    How do things stand with the development of topical agents for HIV prevention? In the age of oral pre-exposure prophylaxis (PrEP) and treatment as prevention, does it matter anymore? And if lessons learned by researchers in the VOICE (Vaginal and Oral Interventions to Control the Epidemic) trial -- discussed most often in terms of its failure -- help make future HIV clinical trials more effective, can we really call it a failure?

    02 November 2015 | The Body Pro
  • Superhero Vaginal Bacteria Species Traps HIV, Could Be a Natural Condom Someday

    The benevolent powers of the vaginal microbiome are even greater than we thought. In addition to aiding fertilization and protecting fetuses during pregnancy, healthy vaginal mucus that’s full of good bacteria can trap and immobilize HIV particles. The study examined the cervicovaginal mucus, or CVM, of 31 women and tested its ability to immobilize HIV particles. CVM samples that contained higher concentrations of D-lactic acid, which only bacteria can produce, did far better than others. The D-lactic acid wasn’t itself a barrier to HIV, but an indicator of something else going on that made certain types of CVM better at trapping the virus than others. That something was Lactobacillus crispatus, a species of bacteria that could change the way we think about HIV prevention.

    08 October 2015 | Slate
  • ICAAC 2015: Combination Vaginal Ring May Be Able to Prevent Both HIV and Herpes

    An experimental silicone vaginal ring with separate compartments may be able to deliver both tenofovir for prevention of HIV infection and acyclovir for prevention of genital herpes and potentially other sexually transmitted infections (STIs), according to a report at the 55th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) last weekin San Diego.

    28 September 2015 | HIVandHepatitis.com
  • 'HIV gel' effective against herpes

    A microbicide gel initially intended to offer protection against HIV has been found to be effective against herpes. Herpes is one of the most common sexually transmitted diseases in South Africa. In the latest study, published in the New England Journal of Medicine, researchers from the Centre for the Aids Programme of Research in South Africa (Caprisa) showed that Tenofovir gel halved the risk of developing herpes simplex virus type 2 – a virus that is a leading cause of genital ulcers.

    13 August 2015 | Independent Online (South Africa)
  • Investment in post-efficacy R&D critical for PrEP, other new HIV prevention options

    HIV Prevention Research & Development Funding Trends 2000–2014: Investment Priorities To Fund Innovation In An Evolving Global Health And Development Landscape is the 11th annual report by the Working Group, a collaboration among AVAC, UNAIDS, and the International AIDS Vaccine Initiative (IAVI). The report summarizes investment in HIV prevention research across eight prevention options, as well as HSV-2 vaccine and HIV cure and therapeutic vaccine R&D.

    19 July 2015 | AVAC
  • Researchers complete ASPIRE Phase III trial of vaginal ring for HIV prevention in women

    In a first for HIV prevention, researchers have completed follow-up of participants in a pivotal Phase III trial that tested a vaginal ring for preventing HIV in women. The ring, which contains the ARV dapivirine, is meant to be worn for a month at a time. More than 2,600 African women took part in ASPIRE, one of two Phase III trials designed to support potential licensure of the ring. Results are expected early 2016.

    29 June 2015 | Eurekalert Medicine & Health
  • York trials new HIV prevention method

    Scientists at the University of York, in conjunction with the York Clinical Research Facility, will start the first phase of trials looking into a new way to prevent HIV transmission.

    18 February 2015 | HIV / AIDS News From Medical News Today
  • Failed Trial in Africa Raises Questions About How to Test HIV Drugs

    The failure of the VOICE trial of H.I.V.-prevention methods in Africa — and the elaborate deceptions employed by the women in it — have opened an ethical debate about how to run such studies in poor countries and have already changed the design of some that are now underway.

    05 February 2015 | New York Times
  • Uganda: High Hopes Ahead of Microbicide Trial Results

    HIV/Aids researchers are anticipating positive results from a large-scale trial assessing the efficacy of a vaginal microbicide gel in preventing HIV infection in women.

    21 January 2015 | AllAfrica.com
More news

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.